Literature DB >> 21647915

Transmastoid extradural-intracranial approach for repair of transtemporal meningoencephalocele: a review of 31 consecutive cases.

Maroun T Semaan1, David A Gilpin, Daniel P Hsu, Jay K Wasman, Cliff A Megerian.   

Abstract

OBJECTIVE: To review the clinical presentation, surgical techniques, and outcomes of the transmastoid extradural-intracranial (TMEDIC) approach for the treatment of transtemporal meningoencephalocele. HYPOTHESIS: The TMEDIC is a safe and effective approach to repair meningoencephalocele originating from the middle or posterior cranial fossa. STUDY
DESIGN: Retrospective chart review.
SETTING: Academic neurotologic tertiary referral center. PATIENTS: Thirty-one consecutive patients diagnosed with transpetrous meningo(encephalo)cele, with or without cerebrospinal fluid leak, between January of 2003 and October of 2010. INTERVENTION: TMEDIC approach for repairing herniated neural tissue through the tegmen or posterior fossa plate using the combination of autologous cartilage, fascia, and tissue sealant. MAIN OUTCOME MEASURES: Anatomic location, size, and number of defects, presence of herniated brain tissue, pre- and postoperative hearing thresholds, and failure rate.
RESULTS: Mean age was 62 ± 26 years. The etiology was spontaneous in 25/31 (80%), congenital in 3/31 (10%), chronic otitis media in 2/31 (6%), and posttraumatic in 1/31 (4%). Posttympanostomy tube clear otorrhea was the presenting sign in 21/31 (68%) of patients. The mean duration of symptoms was 26 months (range: 1-240). The defect involved the middle fossa (MF) floor in 25/31 (90%). Both the tegmen tympani and mastoideum were involved in 12/31 (39%) of patients and multiple dehiscences were seen in 7/31 (22%). In 17/31 (55%) of cases the size exceeded 1 cm. No recurrences were seen.
CONCLUSION: The TMEDIC is a safe and effective method to repair transtemporal meningoencephalocele obviating the need for a middle fossa craniotomy in certain cases.
Copyright © 2011 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21647915     DOI: 10.1002/lary.21887

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  7 in total

1.  Transmastoid Repair of Spontaneous Cerebrospinal Fluid Leaks.

Authors:  Enrique Perez; Daniel Carlton; Matthew Alfarano; Eric Smouha
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-11

2.  Middle Cranial Fossa Encephalocele and Cerebrospinal Fluid Leakage: Etiology, Approach, Outcomes.

Authors:  Beth McNulty; Christopher A Schutt; Dennis Bojrab; Seilesh Babu
Journal:  J Neurol Surg B Skull Base       Date:  2019-05-28

3.  Combined approach for tegmen defects repair in patients with cerebrospinal fluid otorrhea or herniations: our experience.

Authors:  Daniele Marchioni; Marco Bonali; Matteo Alicandri-Ciufelli; Alessia Rubini; Giacomo Pavesi; Livio Presutti
Journal:  J Neurol Surg B Skull Base       Date:  2014-05-02

4.  Surgical management of spontaneous cerebrospinal fluid leakage through temporal bone defects--case series and review of the literature.

Authors:  Lior Gonen; Ophir Handzel; Nir Shimony; Dan M Fliss; Nevo Margalit
Journal:  Neurosurg Rev       Date:  2015-09-05       Impact factor: 3.042

5.  Outcomes after mini-craniotomy middle fossa approach combined with mastoidectomy for lateral skull base defects.

Authors:  Amit Walia; Daniel Lander; Nedim Durakovic; Matthew Shew; Cameron C Wick; Jacques Herzog
Journal:  Am J Otolaryngol       Date:  2020-10-24       Impact factor: 1.808

6.  Recurrent Otogenic Intracranial Sepsis: A Key Radiological Finding, Not to Be Missed.

Authors:  Mark Aziz; Eugene Omakobia
Journal:  Case Rep Otolaryngol       Date:  2019-05-26

7.  Management of tegmen defects with mastoid and epitympanic obliteration using S53P4 bioactive glass.

Authors:  Françoise Remangeon; Ghizlene Lahlou; Lauranne Alciato; Frederic Tankere; Isabelle Mosnier; Olivier Sterkers; Nadya Pyatigorskaya; Daniele Bernardeschi
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-03-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.